semaglutide advisory committee FDA Peptide July 2026 209637Orig1s000

References: The Global Use of Medicines Outlook Through 2029

Noom breaks the GLP-1 cost cycle with two innovative solutions Noom is tackling the problem of GLP-1 availability, accessibility and inflated costs by launching two distinct solutions for employers that reduce obesity management costs while enabling access to life-changing medications: Noom Med with SmartRx in partnership with Waltz Health, and Noom Weight with GLP-1Rx

With the rise of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, conversations surrounding their inclusion in employee benefits programs are expanding in new directions.

One seen as easier: GLP-1 medications. Since the beginning of time, people...

Unlike FDA-approved medications (e.g., Wegovy, Ozempic, Zepbound), compounded alternatives lack agency review for safety, quality, and efficacy

What is HCG